What are some realistic expectations that can come from the Accelerating Medicines Partnership?

Opinionconversations48254827Autoimmune diseases affect 50 million Americans and are a leading cause of death and disability — yet we have no cure. Historically, the first goal of treatment is to reduce inflammation focusing on making quality of life as good as possible. However, more needs to be done on greater research options for all autoimmune disease-related patients. In existing research, 80-100 different autoimmune diseases have been identified and researchers suspect at least 40 additional diseases of having an autoimmune basis. These diseases are chronic and can be life-threatening. The American Autoimmune Related Diseases Association (AARDA) is excited about the newly announced partnership between NIH, 10 biopharmaceutical companies, numerous non-profits and PhRMA to create the Accelerating Medicines Partnership (AMP). The goals of the AMP are a small victory for champions of increased research and hopefully treatment options, as well as reducing the time to develop these new methods for patients suffering from all types of autoimmune diseases. With additional research, discovery, and collaboration to take place under AMP, patients of rare autoimmune diseases could see new found hope – and everyone can agree that’s a good thing. The AMP will begin with three to five year pilot projects including the autoimmune disorders of rheumatoid arthritis and systemic lupus erythematosus (lupus) as well as Alzheimer’s disease and type 2 diabetes. Research conducted could...
Source: PHRMA - Category: Pharmaceuticals Authors: Source Type: news